HADYFENZ

Class [005]
Pharmaceutical Products

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema,fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasmafractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment andprevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparationsfor the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment ofhemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia;blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinarymedicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kitsconsisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cellcultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells formedical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations forthe treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations,namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibodyfor the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely,antibody for the treatment of Hereditary Angioedema, HAE